Completed PHASE4 INTERVENTIONAL 3-arm NCT00941148

Beta-Cell Function of Insulin Glargine Compared to Neutral Protamine Hagedorn (NPH) Insuline and to Insulin Detemir in Combination With Metformin

Impact of Insulin (I.)Glargine Compared to NPH I. and to I. Detemir in Combination With Metformin on Prandial ß-cell Function and Overall Metabolic Control in Type 2 Diabetic Patients With Insufficient Metabolic Control During OAD Treatment

Sponsor: IKFE Institute for Clinical Research and Development

Conditions Insufficient Metabolic Control OAD Treatment Type 2 Diabetic Patients

Interventions Insulin Glargin Insulin detemir NPH insulin metformin

Updated 4 times since 2017 Last updated: Jul 16, 2009 Started: Apr 30, 2008 Primary completion: Mar 31, 2009 Completion: Mar 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Insufficient Metabolic Control and OAD Treatment and is currently completed. IKFE Institute for Clinical Research and Development leads this study, which shows 4 recorded versions since 2008 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jan 2017 — Jan 2021 [monthly]

Completed PHASE4

First recorded

Apr 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

IKFE Institute for Clinical Research and Development
ikfe-CRO GmbH

Data source: ikfe-CRO GmbH

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Mainz, Germany